Reglitazar
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 170861-63-9
- Formule: C22H20N2O5
- Masse moléculaire:392.40
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | EC50 |
1.1 x 10-7M
Compound: 2 (JTT-501)
|
Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
|
[PMID: 9599241] |
Chemical Information
-
CAS No. 170861-63-9
-
Masse moléculaire 392.40
-
Formule C22H20N2O5
-
SMILES
O=C(C1CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)NOC1=O
-
Synonyms
JT 501
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Reglitazar Related Classifications
HY-101637 Related Classifications
Powered by Bioz